November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Clinical Trial Finds Tirzepatide Lowers BMI in Adolescents with Obesity

🏃 Fitness 2 min read 👁 5

A recent Phase III clinical trial evaluated the once-weekly injectable drug tirzepatide in teenagers with obesity, revealing significant reductions in body mass index and improvements in metabolic health markers over 72 weeks.

Clinical Trial Finds Tirzepatide Lowers BMI in Adolescents with Obesity🏃Fitness

Photo: Medical Xpress

Key points

  • Phase III SURMOUNT-ADOLESCENTS trial tested tirzepatide across 160 teenagers in six countries.
  • Participants on the drug saw an average BMI reduction of 18.5% over 72 weeks.
  • Over half of the teenagers taking tirzepatide moved below the clinical obesity threshold.

A recent Phase III clinical trial, designated SURMOUNT-ADOLESCENTS, evaluated the effectiveness of the once-weekly injectable medication tirzepatide in teenagers struggling with obesity or overweight conditions accompanied by related health complications. Conducted across 31 medical centers in six countries including the U.S., Canada, and Italy, the study enrolled 160 participants aged 12 to under 18. Patients were randomly assigned to receive either weekly injections of tirzepatide or a placebo, alongside lifestyle counseling focused on balanced nutrition and physical activity.

After 72 weeks of treatment, adolescents receiving tirzepatide experienced an average BMI reduction of 18.5%, contrasted with a 0.5% increase in the placebo group. Furthermore, approximately 54% of the participants taking the dual-action medication moved below the clinical obesity threshold for their age and sex, compared to just 7% of those given the placebo. Trial data also indicated improvements in physical comfort during daily tasks and favorable shifts in blood markers, including reduced blood pressure and improved cholesterol profiles.

The study highlights important considerations regarding safety and scope, as roughly 81.5% of the treatment group experienced mostly mild to moderate digestive side effects. Researchers also noted that adolescent height growth and puberty progression continued normally throughout the study period. Because obesity is a complex chronic condition affecting roughly one in five teenagers in the U.S., clinical experts emphasize that pharmacological options are generally studied as an addition to, rather than a replacement for, lifestyle interventions.

What to know: Tirzepatide mimics natural gut hormones to help regulate appetite and blood sugar, but like all medical therapies, it carries potential side effects and requires professional oversight. Readers should consult a qualified healthcare provider for personalized medical advice regarding adolescent weight management.

Source Medical Xpress — medicalxpress.com/news/2026-11-tirzepatide-teens-obesity-threshold-clin… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.